Back to Search
Start Over
First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.
- Source :
- Cancer (0008543X); Jan2018, Vol. 124 Issue 2, p315-324, 10p
- Publication Year :
- 2018
-
Abstract
- <bold>Background: </bold>Phosphoinositide 3-kinase (PI3K) β is the dominant isoform for PI3K activity in many phosphatase and tensin homolog (PTEN)-deficient tumor models. This was a first-in-human study to determine the maximum tolerated dose, safety, pharmacokinetics (PK), pharmacodynamics, and preliminary activity of SAR260301, a potent PI3Kβ-selective inhibitor (clinicaltrials.gov identifier NCT01673737).<bold>Methods: </bold>Successive cohorts of patients with advanced solid tumors received increasing doses of oral SAR260301 according to a Bayesian escalation with an overdose-control process based on the occurrence of dose-limiting toxicity in the first 28-day cycle. Adverse events, tumor response, PK, and the effect of food on PK were evaluated. Target engagement was assessed in platelets. Physiologically-based PK modeling was used for exposure predictions.<bold>Results: </bold>Twenty-one patients received treatment at doses ranging from 100 mg once daily to 440 mg/m2 twice daily. Dose-limiting toxicities included 1 episode of grade 3 pneumonitis (400 mg twice daily) and 1 grade 3 γ-glutamyltransferase increase (600 mg twice daily). The maximum tolerated dose was not reached. The most frequently occurring treatment-related adverse events were nausea, vomiting, and diarrhea (14% each). Pharmacologically active concentrations were reached, but SAR260301 was rapidly cleared, and exposures associated with antitumor activity in preclinical models were not maintained at the highest dose tested. Food further decreased SAR260301 exposure.<bold>Conclusions: </bold>SAR260301 had an acceptable safety profile, but exposure sufficient to inhibit the PI3K pathway was unachievable because of rapid clearance, and clinical development was terminated. These results demonstrate the importance of PK and pharmacodynamic assessments in early drug development. Cancer 2018;124:315-24. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Subjects :
- TUMORS
DRUG efficacy
PHARMACOKINETICS
PHARMACODYNAMICS
DRUG metabolism
TOXICITY testing
DRUG interactions
PATIENTS
CLINICAL trials
COMPARATIVE studies
DRUG dosage
DRUG toxicity
HETEROCYCLIC compounds
RESEARCH methodology
MEDICAL cooperation
PHOSPHOTRANSFERASES
PROBABILITY theory
RESEARCH
EVALUATION research
CHEMICAL inhibitors
INDOLE compounds
THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 0008543X
- Volume :
- 124
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Cancer (0008543X)
- Publication Type :
- Academic Journal
- Accession number :
- 127216388
- Full Text :
- https://doi.org/10.1002/cncr.31044